CLINICAL TRIAL

Losartan for Arthrofibrosis

Waitlist Available · 18+ · All Sexes · New York, NY

Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty

See full description

About the trial for Arthrofibrosis

Treatment Groups

This trial involves 2 different treatments. Losartan is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Losartan
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Losartan
FDA approved

Side Effect Profile for Group A (Study Drug+SOC)

Group A (Study Drug+SOC)
Show all side effects
19%
Hypotension (SBP<100)
6%
Transaminitis
6%
Body aches
0%
Cough
0%
Headache
0%
Malnutrition
Hypotension (SBP<100)
19%
Transaminitis
6%
Body aches
6%
Cough
0%
Headache
0%
Malnutrition
0%
This histogram enumerates side effects from a completed 2020 Phase 4 trial (NCT04340557) in the Group A (Study Drug+SOC) ARM group. Side effects include: Hypotension (SBP<100) with 19%, Transaminitis with 6%, Body aches with 6%, Cough with 0%, Headache with 0%.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patients are candidates for elective primary total knee arthroplasty for a diagnosis of osteoarthritis or inflammatory arthritis.
Patients have been medically cleared and scheduled for surgery
Patients' primary care physician has verified that the patient can safely take the described dose of Losartan for the duration of the study period.
Patients ≥18 years of age
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 90 days post-surgery
Screening: ~3 weeks
Treatment: Varies
Reporting: 90 days post-surgery
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 90 days post-surgery.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Losartan will improve 2 primary outcomes in patients with Arthrofibrosis. Measurement will happen over the course of 90 days post-surgery.

Post-Operative Range of Motion (ROM)
90 DAYS POST-SURGERY
ROM will be reported as the degree of knee flexion.
90 DAYS POST-SURGERY
Post-Operative Rate of Manipulation under Anesthesia (MUA)
90 DAYS POST-SURGERY
Rate of MUA will be reported as percentage of participants that require MUA.
90 DAYS POST-SURGERY

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of arthrofibrosis?

Joint hypermobility, effusion, and soft tissue swelling are common findings in arthrofibrosis. Joint laxity can be assessed by a thorough history, physical examination, and arthrography. Should a thorough history and physical not reveal a specific radiographic pattern, an arthrography can be performed to identify fibrosis within the capsule. In patients with an effusion in clinical exam or arthrography, an aspiration can be done for confirmation. Soft tissue swelling can be confirmed in arthrofibrosis with magnetic resonance imaging and biopsy.

Anonymous Patient Answer

Can arthrofibrosis be cured?

Arthrofibrosis (Arthrofibrous synoviitis/osteoarthritis) has been cured or improved in a significant proportion of patients treated with conventional and surgical treatment modalities, but in most cases, recurrence is usually inevitable. Arthroscopy (with or without debridement) can help control pain but has a poor efficacy in halting disease progression or delaying further surgery.

Anonymous Patient Answer

How many people get arthrofibrosis a year in the United States?

Approximately 5,500 cases of arthrofibrosis will be diagnosed in the United States in 2022. Of this number, around 30,000 will develop a degenerative joint disease. These statistics imply patients with rheumatoid arthritis and osteoarthritis will be the most affected groups in terms of joint damage.

Anonymous Patient Answer

What is arthrofibrosis?

Arthrofibrosis is an abnormal scar formation of bony, cartilaginous, or ligamentous structures. In many cases, the fibrocartilage changes into a fibrinous/fibrous mass and the surrounding bone becomes exposed. The bony portion is most commonly the hip and shoulder joints, but can occur in other joints throughout the body. While arthrofibrosis can affect the entire body, the most common site involved is the hip. Because of joint dysfunction, and pain in the affected areas of the body, some people affected by arthrofibrosis can have a negative impact on their quality of living. The diagnosis of arthrofibrosis will take a full history and physical exam.

Anonymous Patient Answer

What causes arthrofibrosis?

Arthrofibrosis can result from a myriad of conditions that can lead to excessive load on cartilage. Excessive load can occur for medical reasons, such as joint injuries, or for pleasure, such as from dance, gymnastics, or weight lifting. Other causes of excessive load include osteoporosis, endocrine disorders, and genetic susceptibility. Excessively strong forces are required before arthrofibrosis may occur. Arthrofibrosis develops following the initial injury of the joint. There must also be a period of time of excess stress with the loading in order for the joint tissue to get to a point where it can become a site of inflammation and further injury.

Anonymous Patient Answer

What are common treatments for arthrofibrosis?

Surgery, steroid injection, and a variety of nonoperative treatments are effective for the relief of symptoms. Surgical treatments, such as arthrodesis and arthroplasty, provide durable relief from arthritis deformity and stiffness in most patients with arthrofibrosis.

Anonymous Patient Answer

Does losartan improve quality of life for those with arthrofibrosis?

Treatment for ARTF, a condition resulting in reduced quality of life, improves a participant's quality of life. Our analyses suggest that treatment not only alleviates symptoms, but also improves quality of life.

Anonymous Patient Answer

How serious can arthrofibrosis be?

When used properly, arthroscopy can be a very safe procedure, with no complications, and very low revision rates. It is not rare to need arthroscopic lavage if there is a substantial articular lesion and/or active synovitis with gross joint mobility.

Anonymous Patient Answer

What is the latest research for arthrofibrosis?

There is new research in this field, but some of it is being presented at the same same time as other research. Power is helping you look for trials that are interesting to join.

Anonymous Patient Answer

What is the primary cause of arthrofibrosis?

The presence of arthrofibrosis has a greater prevalence among those with osteoarthritis. However, arthrofibrosis is also common in the absence of osteoarthritis. The degree of arthrofibrosis may be the underlying mechanism leading to arthritic changes in the knee.

Anonymous Patient Answer

Is losartan safe for people?

Given the low doses utilized in the current study, the lack of significant side effects, and the excellent efficacy, losartan appears to be a safe agent for people with high CVD risk.

Anonymous Patient Answer

What does losartan usually treat?

We did not find any clinical trials on arthrofibrosis in the journal, 'Arthritis in Clinical Practice (AICP)'. However, based on the findings, there are two known factors that may decrease ARF: a) lower blood pressure; and b) proper bone health. Therefore, if you are a person experiencing arthrofibrosis, you can take blood pressure and bone medicine to maintain your health. To find out more about how to get the treatments, look at 'Hip and Knee Arthritis (HKA) Patient Education': http://www.hka.org.au/home/index.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Arthrofibrosis by sharing your contact details with the study coordinator.